{"basic_info": {"ticker": "9969", "exchange": "XHKG", "bloomberg_ticker": "9969 HK Equity", "name": "INNOCARE PHARMA LTD", "industry": "Biotechnology", "name_chinese_simplified": "诺诚健华", "period": "2020", "market_value": 17455296512, "total_income": 1364000, "ccy": "人民币元", "shariah_compliance_summary": "compliant"}, "business_activity_screening": {"summary": [{"shariah_compliance": "compliant", "income": 1364000, "business_income_over_total_income": 1.0}, {"shariah_compliance": "unknown", "income": 0, "business_income_over_total_income": 0.0}], "details": [{"business_activity_cn": "研发服务", "business_activity_en": "R & D services", "income": 1364000, "business_income_over_total_income": 1.0, "shariah_compliance": "compliant"}, {"business_activity_cn": "未分配", "business_activity_en": "Unassigned", "income": 0, "business_income_over_total_income": 0.0, "shariah_compliance": "unknown"}]}, "financial_screening": [{"item": "Debt to Market Capitalization", "amount": 0.04034703982003367, "shariah_compliance": "compliant", "amount_over_market_value": 0.04034703982003367}]}